Your browser doesn't support javascript.
loading
Determinants of sub-optimal glycemic control among patients enrolled in a medicine dispensing programme in KwaZulu-Natal: A cohort study, 2018-2021.
Johnston, Leigh C; Ngassa Piotie, Patrick; Maposa, Innocent; Singh, Sandhya; Kuonza, Lazarus; De Voux, Alex.
Afiliação
  • Johnston LC; South African Field Epidemiology Training Program, National Institute for Communicable Disease, A Division of the National Health Laboratory Service, Johannesburg Division of Epidemiology and Biostatistics, School of Public Health, University of the Witwatersrand, Johannesburg Non-Communicable Disease Directorate, National Department of Health, Pretoria. leighj@nicd.ac.za.
Afr J Prim Health Care Fam Med ; 16(1): e1-e12, 2024 May 31.
Article em En | MEDLINE | ID: mdl-38832377
ABSTRACT

BACKGROUND:

 The Central Chronic Medicines Dispensing and Distribution (CCMDD) programme facilitates clinically stable patients to collect their chronic medication from community-based pick-up points.

AIM:

 We determined baseline glycaemic control and rates and predictors of becoming sub-optimally controlled for type 2 diabetes mellitus (T2DM) CCMDD-enrolled patients.

SETTING:

 The setting of the study was eThekwini, KwaZulu-Natal, South Africa.

METHODS:

 We performed a cohort study (April 2018- December 2021). We linked T2DM CCMDD-enrolled patients to glycated haemoglobin (HbA1c) data from the National Health Laboratory Service. We selected patients optimally controlled at their baseline HbA1c, with ≥ 1 repeat-test available. We used Kaplan-Meier analysis to assess survival rates and extended Cox regression to determine associations between time to sub-optimal control (HbA1c 7%) and predictors. Adjusted hazard ratios (aHRs), 95% confidence interval (CI), and p-values are reported.

RESULTS:

 Of the 41145 T2DM patients enrolled in the CCMDD programme, 7960 (19%) had a HbA1c result available. Twenty-seven percent (2147/7960) were optimally controlled at their baseline HbA1c. Of those controlled at baseline, 695 (32%) patients had a repeat test available, with 35% (242/695) changing to sub-optimal status. The HbA1c testing frequency as per national guidelines was associated with a lower hazard of sub-optimal glycaemic control (aHR 0.46; 95% CI 0.24-0.91; p-value = 0.024). Patients prescribed dual-therapy had a higher hazard of sub-optimal glycaemic control (aHR 1.50; 95% CI 1.16-1.95; p-value = 0.002) versus monotherapy.

CONCLUSIONS:

 The HbA1c monitoring, in-line with testing frequency guidelines, is needed to alert the CCMDD programme of patients who become ineligible for enrolment. Patients receiving dual-therapy require special consideration.Contribution Addressing identified shortfalls can assist programme implementation.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hemoglobinas Glicadas / Diabetes Mellitus Tipo 2 / Controle Glicêmico / Hipoglicemiantes Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Africa Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hemoglobinas Glicadas / Diabetes Mellitus Tipo 2 / Controle Glicêmico / Hipoglicemiantes Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Africa Idioma: En Ano de publicação: 2024 Tipo de documento: Article